Literature DB >> 35035751

Changes of inflammatory factors in patients after resection of lung adenocarcinoma with propofol and etomidate.

Xianjun Zheng1,2, Lai Wei1,2, Gaoyin Kong1,2, Jinyu Jiang1,2.   

Abstract

OBJECTIVE: This research was designed to investigate the changes of inflammatory factors in patients after resection of lung adenocarcinoma with propofol versus etomidate.
METHODS: A total of 104 patients who underwent resection of lung adenocarcinoma in our hospital were divided into a propofol group (group A, n=50) and an etomidate group (group B, n=54). The levels of CRP and IL-6 at different time points and the changes of blood gas indexes at 10 min before and after operation were observed in both groups. Their pain score and quality of life score were compared. Besides, we observed the wake-up time, tracheal extubation time and the incidence of adverse reactions.
RESULTS: The anesthesia recovery and tracheal extubation time in group B were shorter than those in group A (P<0.05). After 10-minutes of spontaneous breathing, PaO2 and SaO2 in group B were higher than those in group A (P<0.05), and PaCO2 was lower (P<0.05); compared with group A. The incidence of adverse reactions and the levels of inflammatory factors in group B were lower than those in group A after operation (both P<0.05). The quality of life of patients in group B after operation was better than that in group A (P<0.05). There was no marked difference in VAS scores between groups.
CONCLUSION: Etomidate has better anesthetic effect than propofol in lung adenocarcinoma resection, leading to better stabilization of the vital signs of patients and it also has higher safety. AJTR
Copyright © 2021.

Entities:  

Keywords:  Propofol; etomidate; inflammatory factors; resection of lung adenocarcinoma

Year:  2021        PMID: 35035751      PMCID: PMC8748119     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  26 in total

1.  Propofol, but not etomidate, increases corticosterone levels and induces long-term alteration in hippocampal synaptic activity in neonatal rats.

Authors:  Changqing Xu; Christoph N Seubert; Nikolaus Gravenstein; Anatoly E Martynyuk
Journal:  Neurosci Lett       Date:  2016-02-26       Impact factor: 3.046

2.  Effect of combined epidural anaesthesia on tumor-infiltrating lymphocytes in lung adenocarcinoma: a prospective exploratory sub-analysis.

Authors:  M-H Li; Z-Z Xu; S-M Huang; T Li; X-Y Li; D-X Wang
Journal:  Acta Anaesthesiol Scand       Date:  2018-01-23       Impact factor: 2.105

3.  Anal Metastasis from Lung Cancer: Report of a Case and Systematic Review of the Literature.

Authors:  Ovidiu D Bardac; Adina-Brînduşa Baciu; Iancu S Bogdan-Duică
Journal:  Chirurgia (Bucur)       Date:  2020 Sept-Oct

4.  miR-139-5p Inhibits Lung Adenocarcinoma Cell Proliferation, Migration, and Invasion by Targeting MAD2L1.

Authors:  Jianfeng Li; Xi He; Xiaotang Wu; Xiaohui Liu; Yixiong Huang; Yuchen Gong
Journal:  Comput Math Methods Med       Date:  2020-11-04       Impact factor: 2.238

5.  Etomidate versus Propofol for Motor Seizure Duration during Modified Electroconvulsive Therapy.

Authors:  Seema Jindal; Gurkaran Kaur Sidhu; Samiksha Kumari; Preeti Kamboj; Rajeev Chauhan
Journal:  Anesth Essays Res       Date:  2020-06-22

6.  IL-6, NLR, and SII Markers and Their Relation with Alterations in CD8+ T-Lymphocyte Subpopulations in Patients Treated for Lung Adenocarcinoma.

Authors:  Lorenzo Islas-Vazquez; Dolores Aguilar-Cazares; Miriam Galicia-Velasco; Uriel Rumbo-Nava; Manuel Meneses-Flores; Cesar Luna-Rivero; Jose Sullivan Lopez-Gonzalez
Journal:  Biology (Basel)       Date:  2020-11-05

Review 7.  Effects of propofol on the development of cancer in humans.

Authors:  Yichi Xu; Shuya Pan; Wenxiao Jiang; Fang Xue; Xueqiong Zhu
Journal:  Cell Prolif       Date:  2020-06-29       Impact factor: 6.831

8.  Clinical observation of the combined use of propofol and etomidate in painless gastroscopy.

Authors:  Lina Hao; Xibei Hu; Bingqing Zhu; Wanhong Li; Xiang Huang; Fang Kang
Journal:  Medicine (Baltimore)       Date:  2020-11-06       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.